- PanTera will supply actinium-225 starting in the second half of 2024.
- PanTera is a joint venture between IBA and SCK CEN.
- The agreement aims to increase access to actinium-225 for clinical trials.
- PanTera is developing a large-scale production facility to meet global demand.
Agreement Overview
PanTera, a Belgian joint venture between IBA and SCK CEN, has signed a capacity reservation agreement with Bayer for the supply of actinium-225 (225Ac). The supply is set to begin in the second half of 2024.
Production and Supply
This agreement marks PanTera's first collaboration with a major drug developer, positioning it as a reliable EU-based supplier of 225Ac. In 2024, PanTera aims to enhance access to 225Ac for clinical trials and develop a large-scale, state-of-the-art production facility to meet the growing global demand.
Strategic Importance
Sven Van den Berghe, CEO of PanTera, highlighted the significance of this development, stating that the ability to supply 225Ac will advance research and clinical trials. The combined expertise and technology from SCK CEN and IBA place PanTera in a unique position to become a leading global supplier of 225Ac for both pre-clinical and clinical trials, as well as commercial use.
Future Plans
PanTera is committed to supporting the pharmaceutical industry by scaling up production to meet the significant global demand for targeted radiopharma-based therapeutics, particularly in the fight against cancer.
